Trial · NCT01406444

IGF-1 and Bone Loss in Women With Anorexia Nervosa

NCT01406444, Not applicable, Completed, Massachusetts General Hospital; results first posted 2020-07-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. IGF-1 and Bone Loss in Women With Anorexia Nervosa. Trials, record NCT01406444. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01406444

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: IGF-1 and Bone Loss in Women With Anorexia Nervosa
NCT number: NCT01406444
Status: Completed
Phases: Not applicable
Enrollment: 148 participants, actual
Lead sponsor: Massachusetts General Hospital
Conditions: Anorexia Nervosa, Osteopenia, Osteoporosis
Interventions: rhIGF-1, Risedronate, Placebo
First posted: 2011-08-01
Last updated: 2020-07-17
Results first posted: 2020-07-17

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Postero-anterior Spine Bone Mineral Density by DXA	12 Months	Postero-anterior spine bone mineral density by dual-energy X-ray absorptiometry
Secondary	Lateral Spine Bone Mineral Density by DXA	12 Months	Lateral spine bone mineral density by dual-energy X-ray absorptiometry

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Postero-anterior Spine Bone Mineral Density by DXA	12 Months		g/cm2	LEAST_SQUARES_MEAN
SECONDARY	Lateral Spine Bone Mineral Density by DXA	12 Months		g/cm2	LEAST_SQUARES_MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Postero-anterior Spine Bone Mineral Density by DXA	rhIGF-1 Followed by Risedronate	0.891	Standard Error 0.014	g/cm2
Postero-anterior Spine Bone Mineral Density by DXA	Risedronate	0.887	Standard Error 0.014	g/cm2
Postero-anterior Spine Bone Mineral Density by DXA	Placebo	0.874	Standard Error 0.013	g/cm2
Lateral Spine Bone Mineral Density by DXA	rhIGF-1 Followed by Risedronate	0.695	Standard Error 0.012	g/cm2
Lateral Spine Bone Mineral Density by DXA	Risedronate	0.677	Standard Error 0.012	g/cm2
Lateral Spine Bone Mineral Density by DXA	Placebo	0.666	Standard Error 0.010	g/cm2

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	rhIGF-1 Followed by Risedronate	33
Overall Study	STARTED	Risedronate	33
Overall Study	STARTED	Placebo	16
Overall Study	COMPLETED	rhIGF-1 Followed by Risedronate	23
Overall Study	COMPLETED	Risedronate	24
Overall Study	COMPLETED	Placebo	14
Overall Study	NOT COMPLETED	rhIGF-1 Followed by Risedronate	10
Overall Study	NOT COMPLETED	Risedronate	9
Overall Study	NOT COMPLETED	Placebo	2

Source ClinicalTrials.gov

Adverse events27

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Injection Site Irritation and/or Bruising	Skin and subcutaneous tissue disorders	rhIGF-1 Followed by Risedronate	15	33	24
other	Injection Site Irritation and/or Bruising	Skin and subcutaneous tissue disorders	Risedronate	11	33	14
other	Injection Site Irritation and/or Bruising	Skin and subcutaneous tissue disorders	Placebo	2	16	2
other	Nausea	Gastrointestinal disorders	rhIGF-1 Followed by Risedronate	1	33	1
other	Nausea	Gastrointestinal disorders	Risedronate	5	33	14
other	Nausea	Gastrointestinal disorders	Placebo	1	16	1
other	Upset Stomach	Gastrointestinal disorders	rhIGF-1 Followed by Risedronate	3	33	3
other	Upset Stomach	Gastrointestinal disorders	Risedronate	1	33	1
other	Upset Stomach	Gastrointestinal disorders	Placebo	0	16	0
other	Acid Reflux	Gastrointestinal disorders	rhIGF-1 Followed by Risedronate	4	33	6

1 to 10 of 27Source ClinicalTrials.gov

See all 27 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	rhIGF-1 Followed by Risedronate	0	33
Total, all-cause mortality	Risedronate	0	33
Total, all-cause mortality	Placebo	0	16
Total, other adverse events	rhIGF-1 Followed by Risedronate	19	33
Total, other adverse events	Risedronate	18	33
Total, other adverse events	Placebo	5	16
Total, serious adverse events	rhIGF-1 Followed by Risedronate	0	33
Total, serious adverse events	Risedronate	0	33
Total, serious adverse events	Placebo	0	16

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01DK052625	IGF-I and Bone Loss in Women with Anorexia Nervosa	KLIBANSKI, ANNE	MASSACHUSETTS GENERAL HOSPITAL	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES	1997 to 2015

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01406444

GET https://conductscience.org/api/trials/v1/NCT01406444/events?page=2

API reference For AI assistants